ImmuneOnco Announced The second Patent Approval by the China Patent Office
On October 29, 2018, the second patent application for new drug invention of ImmuneOncobiopharmaceuticals Co., Ltd. was authorized by China Patent Office (Application No. CN201510203619.7).
The patent involves a CD47 targeted drug, the IMM01 project that has submitted IND applications. This is another major milestone for the company, which indicates that this kind of structured protein drugs will enjoy exclusive market development rights.